{"filing":{"accession_number":"0001104659-26-077060","cik":"0001455365","ticker":"CGTX","company_name":"COGNITION THERAPEUTICS INC","form":"8-K","filing_date":"2026-06-24","report_date":null,"primary_document":"tm2618699d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926077060/tm2618699d1_8k.htm"},"events":[{"id":13367,"run_id":11872,"accession_number":"0001104659-26-077060","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces FDA alignment on key aspects of a pivotal Phase 3 trial design for zervimesine in DLB psychosis, with the registrational program expected to begin in mid-2027. This represents a material regulatory milestone and clinical development advancement for a clinical-stage biopharmaceutical company's lead candidate. While the Item 8.01 header references \"Results of Operations and Financial Condition,\" the actual content is a regulatory/clinical development milestone rather than financial results or operational condition. This is best classified as an operational milestone—a material strategic advancement in the company's clinical development pathway—rather than earnings, impairment, or other financial categories.","company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10491,"accession_number":"0001104659-26-077060","item_number":"8.01","item_title":"Results of Operations and Financial Condition.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA alignment on key aspects of a pivotal Phase 3 trial design for zervimesine in DLB psychosis, with the registrational program expected to begin in mid-2027. This represents a material regulatory milestone and clinical development advancement for a clinical-stage biopharmaceutical company's lead candidate. While the Item 8.01 header references \"Results of Operations and Financial Condition,\" the actual content is a regulatory/clinical development milestone rather than financial results or operational condition. This is best classified as an operational milestone—a material strategic advancement in the company's clinical development pathway—rather than earnings, impairment, or other financial categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T11:39:39.640366+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10491,"accession_number":"0001104659-26-077060","item_number":"8.01","item_title":"Results of Operations and Financial Condition.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA alignment on key aspects of a pivotal Phase 3 trial design for zervimesine in DLB psychosis, with the registrational program expected to begin in mid-2027. This represents a material regulatory milestone and clinical development advancement for a clinical-stage biopharmaceutical company's lead candidate. While the Item 8.01 header references \"Results of Operations and Financial Condition,\" the actual content is a regulatory/clinical development milestone rather than financial results or operational condition. This is best classified as an operational milestone—a material strategic advancement in the company's clinical development pathway—rather than earnings, impairment, or other financial categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T11:39:39.640366+00:00","company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","filing_date":"2026-06-24"}]}